Phase 2 Gene Mutation Clinical Trials
50 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 50 trials
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled27 locationsNCT05786924
Recruiting
Phase 2
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled42 locationsNCT06995677
Recruiting
Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Breast CancerMetastatic Breast CancerBreast Neoplasms+6 more
Kristina A. Fanucci297 enrolled1 locationNCT07222215
Recruiting
Phase 2
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Myelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid Leukemia+2 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT04493164
Recruiting
Phase 1Phase 2
Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss
DFNB1AGJB2 Gene MutationGJB2-mediated Hearing Loss
Skylark Bio Inc.10 enrolled2 locationsNCT07627971
Recruiting
Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
Alliance for Clinical Trials in Oncology124 enrolled780 locationsNCT02523014
Recruiting
Phase 2
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Esophageal CancerGastric AdenocarcinomaHER2 Gene Mutation
Memorial Sloan Kettering Cancer Center49 enrolled10 locationsNCT06123338
Recruiting
Phase 2
PH 2 Pemigatinib in SDH-deficient GIST
SDH Gene MutationGastrointestinal Stromal Tumor
Dana-Farber Cancer Institute24 enrolled1 locationNCT07434843
Recruiting
Phase 2
Personalized NK Cell Therapy in CBT
Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Phase 2Phase 3
Spironolactone Improved Children With Gene Mutations Related to NCOR
ASDNCOR Gene MutationsSpironolactone
Qilu Hospital of Shandong University2 enrolled1 locationNCT06678685
Recruiting
Phase 1Phase 2
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
AMLFLT3 Gene Mutation
Institute of Hematology & Blood Diseases Hospital, China66 enrolled1 locationNCT06561880
Recruiting
Phase 2
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce38 enrolled2 locationsNCT06728410
Recruiting
Phase 2
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
Cystic FibrosisCFTR Gene Mutation
Arcturus Therapeutics, Inc.33 enrolled13 locationsNCT06747858
Recruiting
Phase 2
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Solid TumorWilms TumorRhabdoid Tumor+4 more
Memorial Sloan Kettering Cancer Center45 enrolled16 locationsNCT05985161
Recruiting
Phase 2
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
PI3K Gene MutationKRAS G12DVascular Anomalies+15 more
Murdoch Childrens Research Institute50 enrolled2 locationsNCT05983159
Recruiting
Phase 2
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
GIST - Gastrointestinal Stromal TumorKIT Gene Mutation
Jian Li100 enrolled1 locationNCT07559864
Recruiting
Phase 2
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital25 enrolled1 locationNCT07548060
Recruiting
Phase 2
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Salivary Gland CancerHER2 Gene Mutation
Dana-Farber Cancer Institute37 enrolled13 locationsNCT04620187
Recruiting
Phase 1Phase 2
Alectinib Pharmacokinetic in Patients With NSCLC
ALK Gene MutationNon-small Cell Lung Cancer Stage IIIB
Instituto Nacional de Cancerologia de Mexico45 enrolled1 locationNCT05713006
Recruiting
Phase 1Phase 2
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
Autosomal Dominant Optic AtrophyOPA1 Gene MutationHereditary Optic Atrophies+1 more
PYC Therapeutics18 enrolled3 locationsNCT06970106